arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

CITIUS ONCOLOGY, INC.

CTOR

$0.78 ▲ +0.03 (+3.35%) at close

21 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

CITIUS ONCOLOGY, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $78.0M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -80.4% ↘

FCF / Share $-0.04 ↗

Trailing P/E —

Price / Book 2.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

21-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.67M

↓ -57.7% —

Net Income Profit after all expenses

$-5.53M

↑ +16.9% —

FCF / Share Free cash flow per share

$-0.04

↑ +54.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
EPS Growth YoY (%)	-145.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	40.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-14.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-57.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	70.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	16.9% Good ↑ Good Improving Year-over-year change in net income	16.9% Good ↑ Good Improving Year-over-year change in net income	26.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-40.9% Weak ↓ Weak Declining Year-over-year change in net income	-40.9% Weak Weak Year-over-year change in net income	N/M	51.6% Excellent Excellent Year-over-year change in net income	N/M	N/M	-19.9% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—	—	—	—	—
FCF Growth YoY (%)	—	—	—	—	—	—	—	—	—	-58.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Operating Margin (%) (%)	—	-133.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-988%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.9% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-5.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-5.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-5.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-4.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	-331.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2866%)	-140.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1269%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-229.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-186.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.33x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—	—	—	-0.39x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	-0.19x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.28x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Return on Invested Capital (%)	-80.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-16.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	-14.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	10.7% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	—	16918.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-79.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-33.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—
Return on Capital (%) (%)	-28.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-5.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-7.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-0.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	-0.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-15.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-205%)	-9.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-163%)	-11.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-174%)	-20.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-237%)	-18.7% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-225%)	-16.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-208%)	-14.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-198%)	-27.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-23.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	-24.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-264%)	-55.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-468%)	—	—	177.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1080%)	—	—	—	—	0.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-100%)	92.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+519%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Interest Coverage (x)	—	-363.23x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-2.63M	$-7.30M	—	$-112.00	$-112.00	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Revenue per Share (USD)	$0.02	$0.05	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.27	$-0.06	$-0.06	$-0.08	$-0.11	$-0.09	$-0.10	$-0.07	$-0.07	$0.07	$-0.34	$0.02	$0.07	$0.07	$0.12	$0.00	$0.00	—	$0.00	$0.00	—
Free Cash Flow per Share (USD)	$-0.04	$-0.08	—	—	—	—	—	—	—	$-0.04	—	$-0.02	$-0.02	$-0.03	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.38	$0.69	$0.54	$0.45	$0.50	$0.58	$0.64	$0.25	$0.29	$-0.85	$0.38	$-0.00	$0.03	$0.14	$0.14	$-0.01	$-0.01	$-0.01	$-0.00	$-0.01	—
Tangible Book Value per Share (USD)	$0.38	$0.69	$0.54	$0.45	$0.50	$0.58	$0.64	$0.25	$0.29	$-0.85	$0.38	$-0.00	$0.03	$0.14	$0.14	$-0.01	$-0.01	$-0.01	$-0.00	$-0.01	—
Basic Weighted Avg Shares (shares)	100.03M	87.46M	—	71.55M	71.55M	71.55M	—	67.50M	67.50M	4.74M	—	6.60M	6.60M	6.60M	—	1.50M	1.50M	—	—	1.50M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Working Capital (USD)	$-29.39M	$-7.56M	$-21.95M	$-34.68M	$-31.70M	$-26.32M	$-21.73M	—	—	$-1.99M	$-13.31M	—	—	$345.51K	$345.51K	—	—	—	$-10.11K	—	—
Total Equity (USD)	$35.27M	$58.41M	$44.87M	$32.40M	$35.64M	$41.29M	$46.14M	$17.03M	$19.85M	$-1.99M	$25.54M	$-1.97K	$197.59K	$345.51K	$345.51K	$-10.11K	$-10.11K	$-10.11K	$-10.11K	$-10.11K	$-9.39K

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Mar 31, 2026 10-Q ↗	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Sep 30, 2025 10-K ↗	Q3 FY2025 Jun 30, 2025 10-Q ↗	Q2 FY2025 Mar 31, 2025 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Sep 30, 2024 10-K ↗	Q3 FY2024 Jun 30, 2024 10-Q ↗	Q2 FY2024 Mar 31, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Sep 30, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Mar 31, 2021 10-Q ↗
Sales/Revenue/Turnover (USD)	$1.67M	$3.94M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-5.53M	$-5.53M	$-5.00M	$-6.66M	$-6.66M	$-6.66M	$-6.81M	$-4.73M	$-4.73M	$489.83K	$-14.08M	$611.73K	$611.73K	$611.73K	—	—	—	—	$0.00	$-9.39K	—
Operating Cash Flow (USD)	$-3.83M	$-7.35M	—	—	—	—	—	—	—	$-191.69K	—	$-113.47K	$-100.26K	$-168.80K	—	—	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 21 quarters

CITIUS ONCOLOGY, INC.

Analytical Summary

21-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CTOR with peers